FICHIT

Je m'inscris

INNAVIRVAX

0/5 (0 note(s))
Note donnée : aucune
Paris
0
Develops cutting-edge immune-based treatments for high unmet medical needs through our versatile and targeted vaccine platform.
VAC-3S is an immunotherapy, currently in phase 2 clinical trial, that will change the paradigm of HIV therapy allowing patients to undergo functional cure (i.e. stop antiretrovirals therapy).
CROUZET Joel
www.innavirvax.fr
Private Equity

Fiche créée le 10/04/2016 par Guillaume   vue 51 fois.